Abstract
Human induced pluripotent stem cells (iPSC) have the potential to radically reduce the number of animals used in both toxicological science and disease elucidation. One initial obstacle culturing iPSC is that they require daily medium exchange. This study attempts to clarify why and propose some practical solutions. Two iPSC lineages were fed at different intervals in a full growth area (FGA) or a restricted growth area (RGA). The FGA consisted of a well coated with Matrigel™ and the RGA consisted of a coated coverslip placed in a well. Glucose, lactate, extracellular pH and cell cycle phases were quantified. Without daily feeding, FGA cultured iPSC had significantly reduced growth rates by day 2 and began to die by day 3. In contrast, RGA cultured cells grew to confluence over 3 days. Surprisingly, glucose was not exhausted under any condition. However, extracellular pH reached 6.8 after 72 h in FGA cultures. Artificially reducing medium pH to 6.8 also inhibited glycolysis and initiated an increase in G0/G1 phase of the cell cycle, while adding an additional 10 mM bicarbonate to the medium increased glycolysis rates. This study demonstrates that iPSC are highly sensitive to extracellular acidification, a likely limiting factor in maintenance of proliferative and pluripotent status. Culturing iPSC in RGA prevents rapid extracellular acidification, while still maintaining pluripotency and allowing longer feeding cycles.
| Original language | English |
|---|---|
| Pages (from-to) | 445-454 |
| Number of pages | 10 |
| Journal | Toxicology in Vitro |
| Volume | 45 |
| Early online date | 15 Aug 2017 |
| DOIs | |
| Publication status | Published - Dec 2017 |
Funding
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no 115439 (StemBANCC), resources of which are composed of financial contribution from the European Union Seventh Framework Programme ( FP7/2007-2013 ) and EFPIA companies' in-kind contribution. This publication reflects only the author's views and neither the IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein. The financial support by Foundation ProCare , Zürich, Switzerland, is also gratefully acknowledged. The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no 115439 (StemBANCC), resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution. This publication reflects only the author's views and neither the IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein. The financial support by Foundation ProCare, Zürich, Switzerland, is also gratefully acknowledged.
| Funders | Funder number |
|---|---|
| Foundation | |
| Medical Research Council | G0301182 |
| Biotechnology and Biological Sciences Research Council | BB/E012841/1, BB/I020209/1 |
| European Commission | |
| Seventh Framework Programme | |
| Innovative Medicines Initiative | 115439 |
Keywords
- Cell cycle
- Glucose
- Growth arrest
- iPS
- Lactate
- pH